Oasmia Pharmaceutical has announced the appointments of Kia Bengtsson as Head of Clinical Development and Johanna Röstin as Head of Regulatory Affairs with effect from October 1, 2021.
The appointments strengthen Oasmia’s internal drug development expertise as the company progresses its portfolio of cancer therapies through the clinic and evaluates opportunities to further expand the pipeline through M&A and in-licensing, it states.
’’We are delighted to welcome Kia and Johanna to Oasmia as we enter a new phase of clinical development with our oncology portfolio. We’ll also benefit from their extensive industry experience as we continue to broaden our pipeline and establish Oasmia as a leading, sustainable oncology company focused on bringing new treatment approaches to patients,” says Heidi Ramstad, Chief Medical Officer at Oasmia.
Kia Bengtsson was previously Director, Drug Development, at the Swedish nanotechnology company Nanologica, with responsibility for pre-clinical and clinical development. In more than 20 years at leading pharma and biotech companies, Kia has worked on the development of innovative therapies including Somatuline for the treatment of neuroendocrine tumors and Decapeptyl for the treatment of prostate cancer. She held leading positions in drug development and clinical operations at Ipsen, AstraZeneca and Eurocine Vaccines. Kia began her career as a registered nurse at Karolinska University Hospital.
“Oasmia is building a strong oncology-focused business, with important international clinical studies underway and clear ambitions to build a broad cancer portfolio. I look forward to joining the company at this exciting time and to supporting its growth strategy,” says Kia Bengtsson.
Johanna Röstin joins Oasmia from OxThera AB, where she is Director of CMC, Program Management and Regulatory. Johanna spent 10 years at Swedish Orphan Biovitrum AB (Sobi), where she was regulatory responsible for one of Sobi’s leading biological products commercialized in the EU and US as Global Senior Regulatory Affairs Manager. She was Regulatory CMC expert for commercial- and development-stage biological products. She has also worked for Pharmacia and Biovitrum. Johanna has an M.Sc in chemical engineering / biotechnology and a Licentiate degree in biotechnology from the KTH Royal Institute of Technology in Stockholm.
“Oasmia is putting in place a first-class in-house team to help it bring new options to patients with ovarian and prostate cancer and to expand its portfolio of innovative products. This is a great opportunity to help build a leading oncology company focused on innovation,” says Johanna Röstin.